Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Dr Hanny Al-Samkari
Massachusetts General Hospital, Boston, MA, USA
Dr Hanny Al-Samkari is the Peggy S. Blitz Endowed Chair in Hematology/Oncology at the Massachusetts General Hospital (MGH) and an associate professor of medicine at Harvard Medical School in Boston, MA, USA. read more
Dr Al-Samkari is a classical haematologist and National Institutes of Health (NIH)-funded clinical investigator and clinical trialist. He also serves as co-director of the MGH Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence. His clinical and research interests are in haemostasis, thrombosis and haemolysis, with a focus on HHT, immune thrombocytopenia and haemolytic anaemias. As a clinical investigator, Dr Al-Samkari is an internationally recognized expert in the clinical development of novel therapeutics for these disorders and serves as the lead principal investigator for multiple ongoing clinical trials.Â
Dr Al-Samkari is the current executive editor of Hematology: The ASH Education Program, an American Society of Hematology peer-reviewed publication, and he has published over 150 peer-reviewed manuscripts. His original research has featured in The New England Journal of Medicine, The Lancet, Annals of Internal Medicine and Blood, among other top peer-reviewed journals in haematology and medicine.
Dr Hanny Al-Samkari discloses: Consultant fees from Agios, Alnylam, Alpine, Amgen, Argenx, Novartis, Pharmacosmos and Sobi. Grants/research support from Agios, Amgen, Novartis, Sobi and Vaderis.
Dr Drew Provan
Barts and the London School of Medicine and Dentistry, London, UK
Dr Drew Provan is currently emeritus reader in autoimmune haematology at Barts and The London School of Medicine and Dentistry in London, UK. read more
Dr Provan studied molecular genetics at Leicester University before studying medicine. After junior medical posts in the UK, he undertook research at The Dana-Farber Cancer Institute from 1993 to 1994 on an American traveling fellowship awarded by the Medical Research Council.Â
Dr Provan’s main area of interest is immunohaematology which includes immune thrombocytopenia (ITP), neutropenia and haemolytic anaemia. Dr Provan established the UK ITP Registry, a clinical and laboratory database of patients with ITP. This facilitates the collection of clinical information related to adults with ITP throughout the UK in addition to allowing for DNA samples to be obtained for genetic analysis.
Dr Provan, along with international colleagues, published the revised International Consensus guidelines for the diagnosis and management of ITP, published in Blood Advances in 2019. The consensus document is currently being updated and will be published in early 2025. He has written numerous peer-reviewed papers, book chapters and has authored several medical books including Molecular Hematology (Wiley), Oxford Handbook of Clinical Haematology, Oxford Handbook of Clinical and Laboratory Investigation, and the ABC of Clinical Haematology (BMJ books).Â
Dr Drew Provan discloses: Consultant fees from Argenx, Argobio, Candidrx, Dexcel, MedImmune, Nuvig, Ono, Sobi and UCB. Speaker’s bureau fees from Amgen, Grifols, Novartis and Sobi.
Dr Barbara Skopec
University Medical Centre Ljubljana, Ljubljana, Slovenia
Dr Barbara Skopec is senior attending and the head of the Medical Consulting Services and Outpatient Clinic at the Haematology Department at the University Medical Centre Ljubljana in Slovenia. She is also a teaching assistant at the Division of Haematology at the University of Ljubljana Faculty of Medicine. read more
Dr Skopec obtained her medical degree from the Faculty of Medicine, University of Ljubljana in 2002 before completing her residency in internal medicine in 2009 and subspecializing in haematology in 2018. She completed her PhD in the field of haematology at the University of Ljubljana. Dr Skopec’s research interests mainly include multiple myeloma and immune thrombocytopenia. She has worked as a visiting fellow at Weill Cornell Medical School, New York, USA with Professor James Bussel. She is a member of the European Hematology Association, American Society of Hematology and European Society for Bone and Marrow Transplantation as well as the general secretary of the Slovenian Society of Haematology.Â
Dr Barbara Skopec discloses: Advisory board or panel fees from AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, Sobi and Takeda. Consultant fees from AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, Sobi and Takeda. Speaker’s bureau fees from AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, Sobi and Takeda.
